iMAb delivers readily developable human antibodies for your pipeline

SERVICES


Antibody development includes:

  • In vitro selection and screening (on cells, proteins or peptides)
  • Human/mouse cross-reacting mAb
  • IgG reformatting (#species, #isotype, Fc KO or ADCC-enhanced)
  • Functional validation (agonist/antagonist/competition/inhibition/ADCC/CDC/...)

TECHNOLOGY


In vitro display technologies offer unique advantages over hybridoma technology, particularly for challenging targets like integral membrane proteins.

 

iMAb uses proprietary computer-designed synthetic repertoires of human mAbs optimized for diversity, expression, and affinity for in vitro screening.

ABOUT US


iMAb is a biotech company with an integrated approach to develop human antibodies.
 
The company was spun out from Inserm and uses proprietary know-how and a highly diverse library containing billions of candidate antibodies.


Highlights


  • Recognized team of experts in antibody discovery
  • Proprietary in vitro optimized human libraries
  • 100% delivery track record as of today*

(*) > 30 (academic) programs including: GPCR agonists, enzyme inhibitors, anti-splicing-variants, anti-post-translational modifications, anti-receptor tyrosine kinases, anti-ligand, ... (many of them cross-reactive human/mouse)

 

Latest news


iMAb - ADC Therapeutics collaboration
April 9, 2019
iMAb and ADC Therapeutics join forces to discover novel therapeutic human antibodies


FESTIVAL OF BIOLOGICS 2019 - San Diego, USA

March 4-5, 2019

Meet iMAb at the Festival of Biologics, at the Americas Antibody Congress bringing together the pioneers doing the most innovative work within the industry and across the whole value chain.


BIO-EUROPE 2018 - Copenhagen, Danmark

November 5-7, 2018

Meet iMAb at the 24th annual BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry


FESTIVAL OF BIOLOGICS 2018 - basel switzerland

October 29-31, 2018

Meet iMAb at the Festival of Biologics, a technology exhibition for the biologics community gathering 1200 antibody, biosimilar, immunotherapy and high potency API development professionals, as well as leading academics and innovative suppliers.